TG Therapeutics, Inc. (TGTX) is a publicly traded Healthcare sector company. As of October 8, 2026, TGTX trades at $52.75 with a market cap of $7.99B and a P/E ratio of 17.47. TGTX moved +0.00% today. Year to date, TGTX is +80.84%; over the trailing twelve months it is +45.07%. Its 52-week range spans $25.28 to $59.30. Analyst consensus is buy with an average price target of $69.17. Rallies surfaces TGTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for TGTX, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $52.75 |
| Market Cap | $7.99B |
| P/E Ratio | 17.47 |
| EPS | $3.10 |
| Dividend Yield | 0.00% |
| 52-Week High | $59.30 |
| 52-Week Low | $25.28 |
| Volume | 85.31K |
| Avg Volume | 0 |
| Revenue (TTM) | $616.29M |
| Net Income | $447.18M |
| Gross Margin | 83.66% |
6 analysts cover TGTX: 0 strong buy, 5 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $69.17.